AtriCure to Announce First Quarter 2016 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the first quarter of 2016 on Thursday,
April 28, 2016.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, April 28, 2016 to discuss its first quarter 2016 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (855)
307-9214 for domestic callers and (330) 863-3275 for international
callers using conference ID number 84690180.

The webcast will be available on AtriCure’s website and a telephonic
replay of the call will be available through May 5, 2016. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. The conference ID number is 84690180.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. AtriCure recently acquired nContact, a leader in minimally
invasive technology for epicardial ablation. nContact’s mission is to
transform the underserved arrhythmia population through a
multidisciplinary epicardial-endocardial ablation approach. Afib affects
more than 33 million people worldwide. For more information visit AtriCure.com
or follow us on Twitter @AtriCure.

Contacts

AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice
President and Chief Financial Officer
awade@atricure.com
or
Investor
Relations Contact
Gilmartin Group
Lynn Pieper, 415-309-5999
lynn@gilmartinir.com